Siglec-3/CD33 Antibody (Gemtuzumab) [Allophycocyanin]
Novus Biologicals, part of Bio-Techne | Catalog # NBP3-28474APC
Recombinant Monoclonal Antibody
![Novus Antibodies Novus Antibodies](https://resources.rndsystems.com/categoryimages/novus_antibodies.jpg)
Conjugate
Catalog #
Key Product Details
Species Reactivity
Human
Applications
ELISA, Flow Cytometry, Functional
Label
Allophycocyanin (Excitation = 620-650 nm, Emission = 660-670 nm)
Antibody Source
Recombinant Monoclonal Human IgG4 Clone # Gemtuzumab
Concentration
Please see the vial label for concentration. If unlisted please contact technical services.
Product Specifications
Immunogen
Siglec-3 / CD33
Clonality
Monoclonal
Host
Human
Isotype
IgG4
Applications for Siglec-3/CD33 Antibody (Gemtuzumab) [Allophycocyanin]
Application
Recommended Usage
ELISA
Optimal dilutions of this antibody should be experimentally determined.
Flow Cytometry
Optimal dilutions of this antibody should be experimentally determined.
Functional
Optimal dilutions of this antibody should be experimentally determined.
Application Notes
Optimal dilution of this antibody should be experimentally determined.
Formulation, Preparation, and Storage
Purification
Protein A purified
Formulation
PBS
Preservative
0.05% Sodium Azide
Concentration
Please see the vial label for concentration. If unlisted please contact technical services.
Shipping
The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage
Store at 4C in the dark.
Background: Siglec-3/CD33
Long Name
Sialic Acid Binding Ig-like Lectin 3
Alternate Names
CD33, gp67, Siglec3
Gene Symbol
CD33
Additional Siglec-3/CD33 Products
Product Documents for Siglec-3/CD33 Antibody (Gemtuzumab) [Allophycocyanin]
Product Specific Notices for Siglec-3/CD33 Antibody (Gemtuzumab) [Allophycocyanin]
This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...